Chris Ryan

Amivantamab plus lazertinib was approved in Canada for first-line EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.

China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Perioperative durvalumab plus FLOT improved event-free survival in resectable gastric or gastroesophageal junction cancer.

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

The CHMP has recommended the approval of trastuzumab deruxtecan for HER2-low or HER2-ultralow metastatic breast cancer.

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.

The FDA and European Commission have approved 2 biosimilars referencing denosumab for cancer-related bone loss and other indications.

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

The FDA approved brentuximab vedotin plus lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.

The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.

Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.

Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.